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Abstract
Background Matrix metalloproteinases are catabolic
enzymes that play a key role in the articular cartilage
degeneration evident in degenerative and inflammatory
conditions of articular cartilage. The aim of this study is to
assess the ability of pravastatin to modify matrix metallo-
proteinase (MMP) messenger RNA (mRNA) expression
and enzyme activity in a culture of normal human chon-
drocytes stimulated by interleukin-1b.
Materials and methods Normal human chondrocytes
were stimulated with interleukin (IL)-1b for 6 h to induce
MMP expression, simulating a catabolic state, and then
treated with pravastatin (1, 5 and 10 lM) for a further 18 h
before cell lysates and supernatants were harvested. Cells
stimulated with IL-1b but not treated with pravastatin
served as controls. Real-time polymerase chain reaction
(PCR) was used to assess expression of MMP-3 and MMP-
9 mRNA. MMP enzyme activity was assessed using a
fluorescent MMP-specific substrate. Statistical analysis was
performed using analysis of variance (ANOVA).
Results MMP-3 and MMP-9 mRNA expression was
reduced at all concentrations tested with statistically
significant trends in reduction (p = 0.002 and \0.001,
respectively). Analysis of culture supernatants revealed
that pravastatin treatment led to a reduction in total
MMP activity but not to a statistically significant degree
(p = 0.07).
Conclusions Treatment with pravastatin of stimulated
human chondrocytes leads to significant down-regulation
of selected MMP genes and a non-significant reduction in
MMP enzyme activity. Our results provide further evi-
dence that statins may have a role to play in future treat-
ment of disease affecting articular chondrocytes.
Keywords Articular cartilage  Statins 
Matrix metalloproteinases
Introduction
3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reduc-
tase inhibitors, or statins, a class of drug initially devel-
oped for treatment of hypercholesterolaemia, appear to
offer potential in the treatment of inflammatory diseases
including those affecting articular cartilage [1, 2]. Statins
have been reported to reduce expression of matrix
metalloproteinases (MMPs), catabolic enzymes centrally
implicated in the pathophysiology of osteoarthritis [3–5].
MMPs are a zinc-containing, calcium-dependent family of
enzymes that can cleave matrix components at physiologic
pH and temperature [2, 6]. These enzymes possess all the
properties necessary to degrade the cartilage matrix and
lead to joint degeneration. MMP-3 in particular has been
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shown to be a sensitive predictor of joint inflammation and
cartilage catabolism in diseased joints [7, 8].
To date, no study has examined the effect of pravastatin,
a commonly used statin, on MMP production by human
articular chondrocytes. In this study, we aimed to evaluate
the effect of pravastatin on MMP expression and MMP




IL-1b (R&D Systems, USA) was obtained in a lyophilized
form and reconstituted with sterile phosphate-buffered
saline containing 0.1 % bovine serum albumin. Pravastatin
sodium salt (Sigma, UK) was obtained in a lyophilized
form and reconstituted with sterile water.
Cell culture and treatment
Normal human chondrocytes were obtained commercially
(Promocell, Germany). The cells were obtained from the
normal articular cartilage of a femoral head and cryopre-
served. The chondrocytes were cultured in Chondrocyte
Growth Media (Promocell, Germany) at 37 C in a
humidified atmosphere of 95 % air and 5 % CO2. At pas-
sage 4, before cell dedifferentiation, cells were seeded into
six-well plates at density of 1 9 105 cells/well and cul-
tured to approximately 80 % confluence prior to treatment.
To investigate the effect of pravastatin treatment, cells
were pre-treated with IL-1b for 6 h, and then treated with
pravastatin for 18 h at 1, 5 and 10 lM. After a total of 24 h
incubation, culture supernatants were removed and stored
and cell lysates were collected. Cells cultured in the pres-
ence of IL-1b, but without pravastatin, served as experi-
mental controls. All treatments were performed in
triplicate.
Stimulation with IL-1b was performed to simulate the
pathophysiology of osteoarthritis in which IL-1b is con-
sidered a key catabolic stimulant for the production of
matrix metalloproteinases [9]. Previous studies focussing
on the in vitro response of articular chondrocytes to statins
have also used IL-1b as a stimulant of catabolic gene
expression and enzyme production, and the treatment times
used in this study were also based on these previous similar
bodies of work [10–13].
Cell proliferation analysis
The effect of pravastatin treatment on chondrocyte prolif-
eration was determined using the CellTiter 96 AQueous
One Solution Cell Proliferation Assay (Promega, UK).
Cells were seeded into 96-well plates at density of
1 9 104 cells/well. At approximately 80 % confluence,
cells were treated for 24 h with varying concentrations of
pravastatin (1, 5 and 10 lM). Cells cultured in the presence
of media, and an equivalent volume of sterile water, served
as experimental controls. Following 24 h of treatment,
20 ll phenazine methosulphate solution was added to each
well, and this was incubated for 4 h at 37 C. The absor-
bance of the culture medium at 490 nm was recorded using
a spectrometer. The cell proliferation of treatment cultures
was reported as a percentage of control cultures.
RNA extraction and reverse transcription
Total RNA was extracted from chondrocytes treated with
IL-1b or pravastatin using the TRI reagent according to the
manufacturer’s instructions (Sigma, Ireland). Contaminat-
ing genomic DNA was removed from RNA samples using
a DNA-freeTM kit (Applied Biosystems, UK), and the
resulting RNA was then converted to complementary DNA
(cDNA) using Enhanced Avian Reverse Transcriptase
(Sigma, Ireland).
Real-time polymerase chain reaction
cDNA served as template for real-time PCR, which was
conducted using a QuantiTect SYBR Green PCR kit
(Qiagen, UK). Using gene-specific primer pairs, mmp3 and
mmp9 gene products were measured using absolute quan-
tification and are reported as a function of crossing time
(Ct), the cycle number at which PCR amplification
becomes linear. mRNA expression was normalised to
control and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) expression resulting in mean fold change values.
Primers were custom made by Sigma Genosys (nucleotide
sequences are presented in Table 1).
Total MMP activity assay
The total MMP activity of culture supernatants was eval-
uated using the MMP-substrate Mca-Arg-Pro-Lys-Pro-Tyr-
Ala-Nva-Trp-Met-Lys(Dnp)-NH2 (Bachem, UK) with a
quencher and a highly fluorescent end. Activity assays
Table 1 A summary of data for mRNA expression of MMP-3 and
MMP-9
MMP-3 mRNA MMP-9 mRNA
1 lM 0.75 (0.03) 1.0 (0.01)
5 lM 0.75 (0.02) 0.83 (0.02)
10 lM 0.76 (0.02) 0.72 (0.04)
Values presented are means with standard deviations in parentheses
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were carried out by incubating 100 ll of substrate (3 lM)
with 10 ll of culture supernatant in 0.05 M Tris–HCl,
0.01 M CaCl2, 0.15 M NaCl, NaN3 (0.02 %), at pH 7.5 for
1 h at 37 C. The reaction was stopped by addition of 20 ll
stopping solution [100 nM ethylenediamine tetraacetic
acid (EDTA), NaN3 (0.02 %), pH 8.0]. Following cleavage
of the quenching moiety, fluorescence was measured at
325 nm excitation and 393 nm emission [14, 15].
Statistical analysis
All data collected were compiled in an Excel database.
Results for mRNA expression and cell viability are dem-
onstrated as a proportion of control (assumed to equal 1).
Results from the MMP activity assay are reported as the
values recorded. Analysis of variance (ANOVA) testing
was used to test for statistically significant trends in the
data. Statistical significance was accepted if p \ 0.05.
Results
Pravastatin treatment resulted in a reduction in MMP-3 and
MMP-9 mRNA expression. MMP-3 mRNA expression
was reduced at all concentrations tested (Fig. 1). ANOVA
testing confirmed a statistically significant trend in this data
(p = 0.002). A statistically significant trend in reduction of
MMP-9 expression was also observed (p \ 0.001) (Fig. 2).
Mean values for MMP-3 and MMP-9 mRNA expression
are presented in Table 1.
This reduction in MMP mRNA expression was accom-
panied by a decrease in MMP activity. Analysis of culture
supernatants revealed that pravastatin treatment led to a
reduction in total MMP activity (Fig. 3). However, this
reduction just failed to achieve statistical significance
(p = 0.07). Data from the fluorescence assay are presented
in Table 2.
An analysis of chondrocyte cell proliferation (CellTiter
96 AQueous One Solution Cell Proliferation Assay)
revealed that cells treated with pravastatin were found
to have a similar rate of proliferation when compared
with control cells. Cell viability at 1, 5 and 10 lM con-
centration was 0.92 (SD 0.03), 0.97 (0.05) and 0.88 (0.02),
respectively.
Fig. 1 Bar graph illustrating the effect of pravastatin concentration
(x) on MMP-3 expression (y) by normal human chondrocytes after
initial stimulation with IL-1b. Gene expression is presented as fold
change relative to control. MMP expression was normalised to
GAPDH. Error bars represent one standard deviation. *p \ 0.05
Fig. 2 Bar graph illustrating the effect of pravastatin concentration
(x) on MMP-9 expression (y) by normal human chondrocytes after
initial stimulation with IL-1b. Gene expression is presented as fold
change relative to control. MMP expression was normalised to
GAPDH. Error bars represent one standard deviation. *p \ 0.05
Fig. 3 Bar graph illustrating the effect of pravastatin concentration
(x) on MMP activity (y) by normal human chondrocytes after initial
stimulation with IL-1b. Cells cultured in the presence of IL-1b only
served as an experimental control. The MMP activity of culture
supernatants was investigated by cleavage of a fluorescent MMP
specific substrate. Data are presented as mean ± standard deviation.
*p \ 0.05
Table 2 Summary of data from the fluorescence assay determining
overall enzyme activity
Control 1 lM 5 lM 10 lM
150.7 151.5 86.7 112.1
42.4 36.3 18.0 4.8
Values presented are means (top) and standard deviations (below)
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Discussion
In this study, we investigated the ability of pravastatin to
reduce MMP expression and activity by IL-1b-stimulated
chondrocytes. The principle finding of this study is that
pravastatin treatment led to a reduction in both MMP gene
expression and MMP activity, although the MMP activity
reduction failed to reach a statistically significant level. The
development of agents capable of reducing or inhibiting the
expression of MMPs could potentially lead to a slowing
down or inhibition of articular cartilage destruction [2, 3].
Statins were originally developed to combat hypercho-
lesterolaemia. However, it has been noted that these drugs
also have anti-inflammatory properties, and efforts have
been made to apply this potential to the treatment of osteo-
arthritis (OA). In recent years, a small number of in vitro and
animal studies have reported the ability of statins to reduce
the gene expression and protein expression of catabolic
enzymes implicated in the pathogenesis of osteoarthritis
[10, 16]. The treatment of osteoarthritic chondrocytes with
simvastatin and mevastatin has shown a reduction in the
expression of MMP-3 [10, 12]. Treatment with atorvastatin
has been shown to reduce both mRNA and protein expres-
sion of MMP-13 [13]. Pravastatin has previously been sug-
gested as a potential treatment based on reduction of selected
inflammatory cytokines in a collagen-induced arthritis
model in mice [17]. As non-steroidal anti-inflammatory
drugs (NSAIDs), the preferred pharmacological agent of
patients suffering from osteoarthritis, confer significant
gastrointestinal, cardiovascular and renal side-effects,
unearthing a more acceptable drug is warranted [18–20].
Pravastatin has been shown to reduce serum levels of
C-reactive protein (CRP) [21]. However, it has not yet been
tested for its ability to down-regulate MMP gene expres-
sion by human chondrocytes nor for its ability to attenuate
MMP activity. In this study we found that treatment with
pravastatin of IL-1b-stimulated chondrocytes resulted
in down-regulation of gene expression of MMP-3 and
MMP-9. Each of these MMPs is able to cleave different
components of the cartilage matrix. The down-regulation
of these MMP genes by pravastatin is consistent with
previous research assessing the efficacy of different statins.
Lazzerini et al. reported on the ability of simvastatin to
attenuate MMP-3 protein expression in cultured osteoar-
thritic chondrocytes [12]. Simopolou et al. found that
treatment with atorvastatin of osteoarthritic chondrocytes
resulted in decreases MMP-13 expression at both gene and
protein levels [13]. In an animal model of osteoarthritis,
Akasaki et al. have shown that intra-articular mevastatin
can attenuate histological degradation, and this may be a
future therapeutic route of administration [10, 16]. Alter-
natively they may be used as an oral augment, as has been
successfully shown in rheumatoid arthritis, although the
pathophysiology of this disease obviously differs [22].
We did notice that a clear dose response was seen in the
down-regulation of MMP-9 expression, but we failed to
detect a similar dose response with MMP-3. Although we
do not have a good explanation for this, it may be related
to the massive up-regulation in MMP-3 expression in
catabolically stimulated normal articular chondrocytes
compared with the significantly lesser up-regulation of
other matrix metalloproteinases [23]. We also note that the
reduction in mRNA production did not necessarily result in
a corresponding decrease in MMP activity. As we used a
non-specific measure of MMP activity, it is plausible that
other enzymes from the MMP class are not suppressed and
remain active. Further work can clarify which other MMP
members are inhibited by pravastatin.
We acknowledge that this is an in vitro assessment and
that in vitro results can be readily criticised for not accu-
rately replicating the in vivo process. However, monolayer
culture remains a reasonable starting point for assessment
of new treatment options and the best possible method
available. We must also acknowledge that the pathophys-
iology of various articular cartilage diseases differs and
IL-1b is not the only driver of catabolic activity. The use of
other stimulants [such as tumour necrosis factor (TNF)-a
for example] may be of assistance, but this would also add
an extra layer of complexity to the analysis when study of
statins as a potential treatment is still just being explored.
In summary, using an in vitro model, we have found that
treatment with pravastatin results in a reduction of MMP-3
and MMP-9 mRNA expression and MMP enzyme activity.
These findings provide further support for use of statins as
a potential treatment of diseases of articular cartilage in
which there is an inflammatory or catabolic component to
the disease process. Although further work is clearly war-
ranted, this may represent an exciting juncture in the
development of new treatments.
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